Literature DB >> 27845276

3D scaffold with effective multidrug sequential release against bacteria biofilm.

Rafaela García-Alvarez1, Isabel Izquierdo-Barba2, María Vallet-Regí3.   

Abstract

Bone infection is a feared complication following surgery or trauma that remains as an extremely difficult disease to deal with. So far, the outcome of therapy could be improved with the design of 3D implants, which combine the merits of osseous regeneration and local multidrug therapy so as to avoid bacterial growth, drug resistance and the feared side effects. Herein, hierarchical 3D multidrug scaffolds based on nanocomposite bioceramic and polyvinyl alcohol (PVA) prepared by rapid prototyping with an external coating of gelatin-glutaraldehyde (Gel-Glu) have been fabricated. These 3D scaffolds contain three antimicrobial agents (rifampin, levofloxacin and vancomycin), which have been localized in different compartments of the scaffold to obtain different release kinetics and more effective combined therapy. Levofloxacin was loaded into the mesopores of nanocomposite bioceramic part, vancomycin was localized into PVA biopolymer part and rifampin was loaded in the external coating of Gel-Glu. The obtained results show an early and fast release of rifampin followed by sustained and prolonged release of vancomycin and levofloxacin, respectively, which are mainly governed by the progressive in vitro degradability rate of these scaffolds. This combined therapy is able to destroy Gram-positive and Gram-negative bacteria biofilms as well as inhibit the bacteria growth. In addition, these multifunctional scaffolds exhibit excellent bioactivity as well as good biocompatibility with complete cell colonization of preosteoblast in the entire surface, ensuring good bone regeneration. These findings suggest that these hierarchical 3D multidrug scaffolds are promising candidates as platforms for local bone infection therapy. STATEMENT OF SIGNIFICANCE: The present study is focused in finding an adequate therapeutic solution for the treatment of bone infection based on 3D multifunctional scaffolds, which combines the merits of osseous regeneration and local multidrug delivery. These 3D multidrug scaffolds, containing rifampin, levofloxacin and vancomycin, localized in different compartments to achieve different release kinetics. These 3D multidrug scaffolds displays an early and fast release of rifampin followed by sustained and prolonged release of vancomycin and levofloxacin, which are able to destroy Staphylococcus and Escherichia biofilms as well as inhibit bacteria growth in very short time periods. This new combined therapy approach involving the sequential delivery of antibiofilms with antibiotics constitutes an excellent and promising alternative for bone infection treatment. Published by Elsevier Ltd.

Entities:  

Keywords:  Biofilm; Combined therapy; Gram-negative bacteria; Gram-positive bacteria; Multidrug 3D scaffold; Sequential antimicrobial delivery

Mesh:

Substances:

Year:  2016        PMID: 27845276     DOI: 10.1016/j.actbio.2016.11.028

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  12 in total

Review 1.  Engineering 3D Models of Tumors and Bone to Understand Tumor-Induced Bone Disease and Improve Treatments.

Authors:  Kristin A Kwakwa; Joseph P Vanderburgh; Scott A Guelcher; Julie A Sterling
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 2.  Scaffolds in the microbial resistant era: Fabrication, materials, properties and tissue engineering applications.

Authors:  Ángel Serrano-Aroca; Alba Cano-Vicent; Roser Sabater I Serra; Mohamed El-Tanani; AlaaAA Aljabali; Murtaza M Tambuwala; Yogendra Kumar Mishra
Journal:  Mater Today Bio       Date:  2022-08-30

Review 3.  Bone Tissue Engineering through 3D Bioprinting of Bioceramic Scaffolds: A Review and Update.

Authors:  Ahmad Taha Khalaf; Yuanyuan Wei; Jun Wan; Jiang Zhu; Yu Peng; Samiah Yasmin Abdul Kadir; Jamaludin Zainol; Zahraa Oglah; Lijia Cheng; Zheng Shi
Journal:  Life (Basel)       Date:  2022-06-16

4.  Mixed-charge pseudo-zwitterionic mesoporous silica nanoparticles with low-fouling and reduced cell uptake properties.

Authors:  Noemí Encinas; Mercedes Angulo; Carlos Astorga; Montserrat Colilla; Isabel Izquierdo-Barba; María Vallet-Regí
Journal:  Acta Biomater       Date:  2018-12-06       Impact factor: 8.947

5.  Ink-jet 3D printing as a strategy for developing bespoke non-eluting biofilm resistant medical devices.

Authors:  Yinfeng He; Jeni Luckett; Belen Begines; Jean-Frédéric Dubern; Andrew L Hook; Elisabetta Prina; Felicity R A J Rose; Christopher J Tuck; Richard J M Hague; Derek J Irvine; Paul Williams; Morgan R Alexander; Ricky D Wildman
Journal:  Biomaterials       Date:  2021-12-30       Impact factor: 15.304

6.  Strontium-releasing mesoporous bioactive glasses with anti-adhesive zwitterionic surface as advanced biomaterials for bone tissue regeneration.

Authors:  Carlotta Pontremoli; Isabel Izquierdo-Barba; Giorgia Montalbano; María Vallet-Regí; Chiara Vitale-Brovarone; Sonia Fiorilli
Journal:  J Colloid Interface Sci       Date:  2019-12-14       Impact factor: 8.128

Review 7.  Potential antibacterial mechanism of silver nanoparticles and the optimization of orthopedic implants by advanced modification technologies.

Authors:  Yun'an Qing; Lin Cheng; Ruiyan Li; Guancong Liu; Yanbo Zhang; Xiongfeng Tang; Jincheng Wang; He Liu; Yanguo Qin
Journal:  Int J Nanomedicine       Date:  2018-06-05

8.  Bioceramics: from bone substitutes to nanoparticles for drug delivery.

Authors:  María Vallet-Regí
Journal:  Pure Appl Chem       Date:  2019-01-29       Impact factor: 2.453

Review 9.  Hard and Soft Protein Corona of Nanomaterials: Analysis and Relevance.

Authors:  Rafaela García-Álvarez; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2021-03-31       Impact factor: 5.076

Review 10.  Mesoporous Bioglasses Enriched with Bioactive Agents for Bone Repair, with a Special Highlight of María Vallet-Regí's Contribution.

Authors:  Antonio J Salinas; Pedro Esbrit
Journal:  Pharmaceutics       Date:  2022-01-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.